

**PB 103 of 2023**

National Health (Minimum Stockholding) Amendment Determination (No. 1) 2023

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 28 September 2023

Nikolai Tsyganov

Assistant Secretary  
Pricing and PBS Policy Branch  
Technology Assessment and Access Division  
Department of Health and Aged Care

Contents

1 Name 1

2 Commencement 1

3 Authority 2

4 Schedules 2

Schedule 1—Amendments 3

National Health (Minimum Stockholding) Determination 2023 3

1 Name

(1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 1) 2023*.

(2) This instrument may also be cited as PB 103 of 2023.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information | | |
| --- | --- | --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | 1 October 2023. | 1 October 2023 |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Minimum Stockholding) Determination 2023

1 After subsection 5(2)

Add:

(3) For the purposes of this section, a brand of pharmaceutical item to which section 99ADHC and therefore 99AEKA of the Act applies, but to which section 99ADD of the Act does not apply, is treated as if data collection periods applied to the brand, and as if the start day for the first data collection period for the brand was the day on which that brand was first determined under subsection 85(6) of the Act.

2 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Acarbose | Tablet 50 mg | Oral | GLYBOSAY | 2 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol | Oral | Alendronate Plus D3 Sandoz | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |

3 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol | Oral | Fosamax Plus 70 mg/140 mcg | between 1 July 2023 and 31 December 2023—1.5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol | Oral | Alendronate Plus D3 Sandoz | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |

4 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amisulpride | Oral solution 100 mg per mL, 60 mL | Oral | Solian Solution | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amisulpride | Tablet 100 mg | Oral | Amisulpride 100 Winthrop | Between 1 October 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Amisulpride | Tablet 400 mg | Oral | Amisulpride 400 Winthrop | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |

5 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atomoxetine | Capsule 80 mg (as hydrochloride) | Oral | APO-Atomoxetine | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Atorvastatin | Tablet 20 mg (as calcium) | Oral | Atorvastatin GH | Between 1 October 2023 and 29 February 2024—0 months stock by reference to usual demand |
| Azathioprine | Tablet 50 mg | Oral | Azathioprine GH | Between 1 October 2023 and 31 January 2024—0 months stock by reference to usual demand |

6 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Captopril | Oral solution 5 mg per mL, 95 mL | Oral | Capoten | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Carboplatin | Solution for I.V. injection 450 mg in 45 mL | Injection | DBL Carboplatin | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |

7 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Cefalexin | Capsule 500 mg (as monohydrate) | Oral | APO-Cephalexin | between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Cefepime | Powder for injection 2 g (as hydrochloride) | Injection | Cefepime-AFT | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |

8 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Clonazepam | Oral liquid 2.5 mg per mL, 10 mL | Oral | Rivotril | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Clopidogrel | Tablet 75 mg (as besilate) | Oral | Clopidogrel GH | Between 1 October 2023 and 29 February 2024—0 months stock by reference to usual demand |
| Clopidogrel with aspirin | Tablet 75 mg (as hydrogen sulfate)-100 mg | Oral | CLOPIDOGREL/ASPIRIN AN 75/100 | Between 1 October 2023 and 31 October 2023—0 months stock by reference to usual demand |

9 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fentanyl | Transdermal patch 8.4 mg | Transdermal | APO-Fentanyl | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Filgrastim | Injection 300 micrograms in 0.5 mL single-use pre-filled syringe | Injection | Neupogen | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Filgrastim | Injection 300 micrograms in 1 mL | Injection | Neupogen | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Filgrastim | Injection 480 micrograms in 0.5 mL single-use pre-filled syringe | Injection | Neupogen | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Filgrastim | Injection 480 micrograms in 1.6 mL | Injection | Neupogen | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |

10 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | Malean | 4 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Entecavir | Tablet 1 mg (as monohydrate) | Oral | ENTAC | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |

11 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fluorometholone | Eye drops containing fluorometholone acetate 1 mg per mL, 5 mL | Application to the Eye | Flarex | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fluorouracil | Injection 2500 mg in 50 mL | Injection | DBL Fluorouracil Injection BP | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |

12 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Gemfibrozil | Tablet 600 mg | Oral | Lipigem | between 1 July 2023 and 31 December 2023—2 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Glimepiride | Tablet 3 mg | Oral | Amaryl | Between 1 October 2023 and 31 December 2023—0 months stock by reference to usual demand |
| Glimepiride | Tablet 4 mg | Oral | Amaryl | Between 1 October 2023 and 31 October 2023—0 months stock by reference to usual demand |

13 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ibuprofen | Tablet 400 mg | Oral | APO-Ibuprofen 400 | between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Imatinib | Capsule 100 mg (as mesilate) | Oral | CIPLA IMATINIB ADULT | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |

14 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Imatinib | Capsule 100 mg (as mesilate) | Oral | Imatinib GH | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Imatinib | Capsule 400 mg (as mesilate) | Oral | CIPLA IMATINIB ADULT | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |

15 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Letrozole | Tablet 2.5 mg | Oral | Letrozole FBM | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Levonorgestrel with ethinylestradiol | Pack containing 21 tablets 150 micrograms-30 micrograms and 7 inert tablets | Oral | Monofeme 28 | Between 1 October 2023 and 31 December 2023—0 months stock by reference to usual demand |

16 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Losartan | Tablet containing losartan potassium 25 mg | Oral | Cozavan | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Macrogol 3350 | Oral liquid 13.125 g in 25 mL with electrolytes, 500 mL | Oral | Movicol Liquid | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |

17 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 5 mg (orally disintegrating) | Oral | APO-Olanzapine ODT | 3 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 5 mg (orally disintegrating) | Oral | Olanzapine ODT generichealth 5 | Between 1 October 2023 and 31 December 2023—0 months stock by reference to usual demand |

18 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ondansetron | Tablet (orally disintegrating) 8 mg | Oral | Ondansetron ODT Lupin | between 1 July 2023 and 31 August 2023—0 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Oxaliplatin | Solution concentrate for I.V. infusion 100 mg in 20 mL | Injection | DBL Oxaliplatin Concentrate | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |

19 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Sozol | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand  (b) after 31 December 2023—5.5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Paracetamol | Tablet 665 mg (modified release) | Oral | CHEMISTS' OWN OSTEO RELIEF PARACETAMOL | Between 1 October 2023 and 31 October 2023—0 months stock by reference to usual demand |
| Pemetrexed | Powder for I.V. infusion 100 mg (as disodium) | Injection | Pemetrexed-AFT | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Pemetrexed | Powder for I.V. infusion 500 mg (as disodium) | Injection | Pemetrexed-AFT | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |

20 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Perindopril | Tablet containing perindopril erbumine 4 mg | Oral | Indosyl Mono 4 | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand  (b) after 31 December 2023—5.5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Perindopril | Tablet containing perindopril erbumine 4 mg | Oral | Perindopril generichealth | Between 1 October 2023 and 31 January 2024—0 months stock by reference to usual demand |
| Perindopril | Tablet containing perindopril erbumine 8 mg | Oral | Perindopril generichealth | Between 1 October 2023 and 31 January 2024—0 months stock by reference to usual demand |

21 Schedule 1

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ranitidine | Syrup 150 mg (as hydrochloride) per 10 mL, 300 mL | Oral | Zantac Syrup | 4 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ranitidine | Syrup 150 mg (as hydrochloride) per 10 mL, 300 mL | Oral | Zantac Syrup | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual PBS demand |

22 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Thiamine | Tablet containing thiamine hydrochloride 100 mg | Oral | Betavit | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Tobramycin | Injection 80 mg in 2 mL | Injection | DBL Tobramycin | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |

23 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Valproic acid | Tablet, crushable, containing sodium valproate 100 mg | Oral | Epilim | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Vancomycin | Powder for injection 1 g (1,000,000 I.U.) (as hydrochloride) | Injection | Vancomycin Viatris | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |
| Vancomycin | Powder for injection 500 mg (500,000 I.U.) (as hydrochloride) | Injection | Vancomycin Viatris | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |

24 Schedule 1

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Voriconazole | Powder for oral suspension 40 mg per mL, 70 mL | Oral | Vfend | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Voriconazole | Tablet 50 mg | Oral | Vfend | Between 1 October 2023 and 30 November 2023—0 months stock by reference to usual demand |